Low-Dose Naltrexone Side Effects: Delayed-Onset Adverse Events Explained

Does low-dose naltrexone cause side effects weeks after starting?

The trial record does not say. Low-dose naltrexone means naltrexone at doses far below the approved 50 mg tablet, typically 0.5 to 6 mg a day and most often 4.5 mg, a dose a 2026 review calls empirically derived rather than evidence-based [1]. HealthRX.com offers compounded low-dose naltrexone by prescription; compounded drugs are not FDA-approved, and FDA does not verify their safety, effectiveness or quality before they are marketed [5].

That 2026 narrative review screened 105 studies, 15 of them randomized trials, across conditions from chronic pain to autoimmune disease, gut disease, post-infectious syndromes, mental health and oncology. It describes LDN as generally well tolerated, while noting that most of the evidence comes from case reports and small studies [1].

The nearest thing to a timing statement comes from the 50 mg tablet label, which says postmarketing data show most events usually occur early in the course of drug therapy and are transient [3]. That describes the 50 mg tablet, not LDN.

What the randomized trials counted

Pooled data. A 2024 meta-analysis of 4 randomized trials with 222 people with fibromyalgia, searched to May 2024, found no significant difference in serious adverse events against placebo. Vivid dreams and nausea were more common with LDN [2].

Twelve months of follow-up. The INNOVA trial randomized 98 women with fibromyalgia to LDN 4.5 mg daily or placebo for 12 months. Adverse events, predominantly mild and transient, were reported by 68.8% of people on LDN and 72% on placebo, and no treatment-related serious events occurred. The report gives overall rates, not the timing of when events began [6].

Tolerability in smaller trials. In a 31-woman crossover trial of 4.5 mg daily, LDN was rated equally tolerable as placebo and no serious side effects were reported [7]. An 8-week crossover pilot in multiple sclerosis enrolled 80 people and 60 completed it; LDN was well tolerated and serious adverse events did not occur [8].

The effects people report most: sleep, dreams, nausea, dizziness

Insomnia, vivid dreams, nausea and dizziness are the effects the 2026 review names most often across LDN studies [1], and the pooled fibromyalgia trials found vivid dreams and nausea significantly more common with LDN than placebo [2].

The 50 mg tablet label's list of events reported in under 1% of subjects in its opioid-addiction trials includes nightmares, bad dreams and alopecia. The label does not say when they occurred or establish that naltrexone caused them [3].

What the labels cover, and why their numbers do not transfer

One approved label covers 50 mg oral tablets for alcohol dependence and opioid blockade; the other covers a 380 mg deep gluteal injection given every 4 weeks [3][4]. Neither gives guidance on LDN doses [1], so their rates describe much higher exposure by different routes.

In an open-label safety study of about 570 people with alcoholism taking 50 mg, new-onset reactions in 2% or more were nausea 10%, headache 7%, dizziness 4%, nervousness 4%, fatigue 4%, insomnia 3%, vomiting 3%, anxiety 2% and somnolence 2% [3]. The tablet label also says naltrexone has not been shown to cause significant increases in complaints in placebo-controlled trials in people known to be opioid-free for more than 7 to 10 days [3].

The injection has its own adverse-event profile, including injection-site reactions: any injection site reaction occurred in 69% versus 50% on placebo in alcohol dependence, and nausea in 33% versus 11% [4]. Those rates describe a 380 mg intramuscular injection and are not LDN rates.

The serious reactions that are documented, and their timing

Precipitated opioid withdrawal. The tablet label lists as contraindications receiving opioid analgesics and being currently dependent on opioids, including being maintained on methadone or buprenorphine [3]. When an opioid-dependent person takes naltrexone, symptoms usually appeared within 5 minutes of ingestion and lasted up to 48 hours; confusion, somnolence, visual hallucinations and fluid losses needing intravenous fluids occurred, and postmarketing cases required hospital admission and sometimes intensive care [3]. The contraindication is written without a dose exception [3][1]. This reaction is immediate, not delayed.

Vulnerability to opioid overdose. After a missed dose, at the end of a dosing interval or after treatment ends, tolerance to opioids is lower, so previously tolerated doses can cause fatal overdose; fatal overdoses have been reported after discontinuing treatment [3][4]. Both labels advise strongly considering an opioid overdose reversal agent such as naloxone or nalmefene [3][4].

Liver injury. Cases of hepatitis and clinically significant liver dysfunction occurred during development and after marketing [3]. The tablet label says studies using up to 300 mg a day found liver-cell injury in a substantial proportion of patients at higher doses [3]. Neither the tablet label nor the injection label carries a boxed warning [3][4]. The injection label says to discontinue in the event of symptoms or signs of acute hepatitis [4].

Mood. Depression, suicidal ideation, suicide attempts and completed suicide have been reported after marketing; the tablet label says no causal relationship has been demonstrated [3].

Injection-specific events. The injection label describes very severe injection site reactions, some requiring surgery or causing scarring, plus eosinophilic pneumonia and hypersensitivity including urticaria, angioedema and anaphylaxis [4].

For LDN itself, safety data in pregnancy and in liver or kidney impairment are sparse [1].

Other claims about late effects

Thyroid changes. A 2022 review of dietary and alternative approaches to thyroid disease found little to no evidence that low-dose naltrexone has any impact on thyroid disorders [9].

A microglial explanation for timing. The proposed mechanisms, including TLR4 antagonism on microglia, brief opioid-receptor blockade with compensatory upregulation of endogenous opioid signalling, and opioid growth factor receptor effects, remain largely theoretical and speculative according to the 2026 review [1][10].

Interactions with other drugs. The tablet label says studies of interactions between naltrexone and non-opioid drugs have not been performed, and advises caution if other drugs are taken at the same time [3]. Naltrexone also blocks opioid-containing medicines, including some cough, cold and antidiarrheal products and opioid analgesics [3].